AB1332 Factors associated to persistence on golimumab in patients with inflammatory arthritis of the biobadaser registry

Mirtha Hernández; S Rodríguez; Rosa Morlà; Carlos Sánchez-Piedra; Fernando Sánchez-Alonso; F. J. Manero; Blanca Garcia-Magallon; Eva Perez-Pampin; Carlos Rodríguez-Lozano; M.D. Ruiz; L. Cea-Calvo; Juan J. Gomez-Reino

doi:https://doi.org/10.1136/annrheumdis-2018-eular.4577

doi.org/10.1136/annrheumdis-2018-eular.4577

AB1332 Factors associated to persistence on golimumab in patients with inflammatory arthritis of the biobadaser registry

,

,

..., Juan J. Gomez-Reino

72

Published: Jun 1, 2018

Abstract

Background

Persistence to treatment may be used as a surrogate marker for long-term treatment success

Objectives

To assess the probability of persistence on golimumab (GOL) up to 5 years after treatment initiation and the factors associated to longer persistence

Methods

BIOBADASER is the Spanish registry of biological drugs of the Spanish Society of Rheumatology and the Spanish Medicines Agency. A data-base analysis...

Paper Fields

Paper Details

Title

AB1332 Factors associated to persistence on golimumab in patients with inflammatory arthritis of the biobadaser registry

DOI

doi.org/10.1136/annrheumdis-2018-eular.4577

Published Date

Jun 1, 2018

Citation AnalysisPro

You’ll need to upgrade your plan to Pro

Looking to understand the true influence of a researcher’s work across journals & affiliations?

Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.

Learn more

Notes

History